Patients’ Demographics and Tumor Characteristics
| Characteristic | Data |
|---|---|
| Sex | |
| Male | 19 (51) |
| Female | 18 (49) |
| Mean age at diagnosis (y) | 61 ± 10 |
| Mean age at inclusion (y) | 66 ± 8.1 |
| Median time since diagnosis (y) | 3.4 (IQR, 1.7–7.7) |
| Primary tumor site | |
| Small intestinal | 23 (62) |
| Pancreatic | 10 (27) |
| Colorectal | 4 (11) |
| Tumor grade | |
| 1 | 12 (32) |
| 2 | 22 (59) |
| 3 | 3 (8) |
| Site of metastasis | |
| Liver | 32 (86) |
| Lymph nodes | 31 (84) |
| Bone | 22 (59) |
| Peritoneum | 12 (32) |
| Pancreas | 3 (8) |
| Lung | 2 (5) |
| Other* | 6 (16) |
| Metastatic sites involved | |
| Median number | 3 (range, 1–5) |
| ≤3 | 25 (68) |
| >3 | 12 (32) |
| Symptoms | |
| Diarrhea | 16 (43) |
| Pain | 15 (41) |
| Fatigue | 11 (30) |
| Flushing | 9 (24) |
| No symptoms | 12 (32) |
| 18F-FDG PET/CT–positive at baseline | 15 (41) |
| Previous treatment lines | 37 (100) |
| Previous treatments | |
| Surgery (including primary tumor resection) | 27 (73) |
| Somatostatin analogs | 36 (97) |
| Targeted therapy† | 11 (30) |
| Chemotherapy | 8 (22) |
| Liver-targeted therapy‡ | 8 (22) |
| Radiotherapy (external-beam radiation) | 4 (11) |
| Interferon | 1 (3) |
| Median number of previous treatment lines (all) | 2 (range, 1–10) |
| Previous systemic treatment lines (excluding somatostatin analogs) | 16 (43) |
| 1 | 10 (27) |
| 2 | 5 (13) |
| 6 | 1 (3) |